13D Filing: Brady John Robert and Stony Hill Corp (STNY)

Page 6 of 9 – SEC Filing

Each of the Reporting Persons intends to review their respective investment in the Issuer on a continuing basis and may engage in communications with one or more stockholders of the Issuer, one or more officers of the Issuer, one or more members of the board of directors of the Issuer and/or one or more other representatives of the Issuer concerning the business, operations and future plans of the Issuer.

None of the Reporting Persons has any present plan or proposal which would relate to or result in:

(a) The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer;

(b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries;

(c) A sale or transfer of a material amount of assets of the issuer or any of its subsidiaries;

(d) Any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

(e) Any material change in the present capitalization or dividend policy of the issuer;

(f) Any other material change in the issuer’s business or corporate structure, including but not limited to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940;

(g) Changes in the issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person;

(h) Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

(i) A class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

(j) Any action similar to any of those enumerated above.

Each of the Reporting Persons may, at any time and from time to time, review or reconsider their respective position and/or change their respective purpose and/or formulate and adopt plans or proposals with respect thereto subject to compliance with applicable regulatory requirements.

Item 5. INTEREST IN SECURITIES OF THE ISSUER.

(a) On the filing date of this Schedule 13D, Mr. Brady beneficially owned, in the aggregate, 2,000,000 shares of common stock, representing approximately 13.1% of the Issuer’s outstanding shares of common stock, based on 15,247,600 shares of common stock issued and outstanding as of June 30, 2017, according to the Quarterly Report on Form 10-Q of the Issuer filed with the Securities and Exchange Commission on August 11, 2017.

On the filing date of this Schedule 13D, the Trust beneficially owned, in the aggregate, 1,600,000 shares of common stock, representing approximately 10.4% of the Issuer’s outstanding shares of common stock, based on 15,247,600 shares of common stock issued and outstanding as of June 30, 2017, according to the Quarterly Report on Form 10-Q of the Issuer filed with the Securities and Exchange Commission on August 11, 2017.

6

Follow Applied Biosciences Corp.